The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BIO | -3.45% | -42.79% | -10.57% | +12,863% |
| S&P | +15.06% | +95.03% | +14.29% | +5,893% |
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $651.60M | 2.1% |
| Gross Profit | $345.40M | -2.9% |
| Gross Margin | 53.01% | -2.7% |
| Market Cap | $6.57B | -15.7% |
| Market Cap / Employee | $0.85M | 0.0% |
| Employees | 7.7K | -4.1% |
| Net Income | $317.80M | 114.7% |
| EBITDA | $130.10M | -11.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $371.30M | -8.8% |
| Accounts Receivable | $469.90M | 5.5% |
| Inventory | 798.8 | -0.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.37B | 1.1% |
| Short Term Debt | $40.60M | -3.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.21% | 15.4% |
| Return On Invested Capital | 1.14% | -10.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $70.80M | 27.9% |
| Operating Free Cash Flow | $116.50M | 19.3% |
| Metric | Q2 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 20.57 | - | |||
| Price to Book | 1.39 | 1.23 | 1.04 | 1.00 | 16.00% |
| Price to Sales | 3.63 | 3.58 | 2.68 | 2.57 | -14.99% |
| Price to Tangible Book Value | 1.56 | 1.36 | 1.16 | 1.12 | 19.38% |
| Price to Free Cash Flow TTM | 37.98 | 31.82 | 19.15 | 17.71 | -69.31% |
| Enterprise Value to EBITDA | 63.58 | 66.42 | 62.00 | 50.74 | -0.96% |
| Free Cash Flow Yield | 2.6% | 3.1% | 5.2% | 5.6% | 225.80% |
| Return on Equity | -9.8% | -24.1% | -27.5% | 4.6% | -126.36% |
| Total Debt | $1.39B | $1.38B | $1.37B | $1.41B | 0.99% |
BIO earnings call for the period ending September 30, 2021.
BIO earnings call for the period ending June 30, 2021.
BIO earnings call for the period ending March 31, 2021.
BIO earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
